Navigation Links
Baron & Budd, P.C., Announces $3.6 Million Settlement in California Asbestos Lawsuit

SAN FRANCISCO, Nov. 5 /PRNewswire/ -- The law firm of Baron & Budd, P.C., is announcing a $3.6 million settlement in an asbestos exposure lawsuit filed on behalf of an 81-year-old man who worked in the San Francisco area. The settlement was reached a day before the jury would have determined the fate of the defendants, all asbestos joint compound companies.

Attorneys John Langdoc and Eric Brown from Baron & Budd represented Martin Lujan. The final settlement was reached after two weeks of trial in Judge Thomas Mellon's courtroom in San Francisco.

The defendants in this trial were: Bondex, Kaiser-Gypsum, Hamilton Materials, and Kelly Moore.

"Eric, John and our entire trial team worked incredibly hard to find and interview witnesses; obtain access to internal corporate files which showed these companies knew their products could cause cancer and chose to keep selling them; and trace Mr. Lujan's career working in the construction of over 100 buildings around these products. In the end the investigation uncovered that Mr. Lujan had been exposed to asbestos, a known carcinogen, in the form of joint compound, for over 15 years while working in the construction industry," says Russell W. Budd, managing partner of Baron & Budd.

In addition to uncovering that Mr. Lujan had been exposed to asbestos from these companies' joint compounds, the Baron & Budd trial team also presented evidence that the companies were told by the U.S. government that working for only four days around joint compounds would result in an unreasonable risk of cancer to workers, and that it has been known for decades that there is no safe level of exposure to asbestos.

Just months before he was diagnosed with mesothelioma, his doctors noted that Mr. Lujan was in excellent health. When his doctors informed him that his mesothelioma was caused by asbestos, he initially had no idea that his work as a carpenter and construction worker had exposed him to dangerous materials.

"Mr. Lujan's family is appreciative of all the hard work put in by the Baron & Budd team to uncover what products were responsible for Mr. Lujan's asbestos cancer," says John Langdoc.

The effects of asbestos exposure, including the onset of diseases like mesothelioma and other asbestos cancers, can take decades to surface. Nearly forty years passed before Mr. Lujan began exhibiting symptoms of mesothelioma. He is currently fighting the cancer from his home in the San Francisco area.

About Baron & Budd, P.C.

For 30 years, the law firm of Baron & Budd, P.C. has championed the rights of people and communities harmed by corporate misconduct. With more than 50 attorneys and offices in California, Texas and Louisiana, Baron & Budd enjoys a national reputation as a leader of the plaintiffs' bar. The firm represents individuals with mesothelioma and other diseases caused by asbestos; leukemia caused by benzene; injuries caused by other toxic substances and unsafe pharmaceuticals; water authorities seeking clean-up costs for drinking water contamination; securities investors defrauded by corporate wrongdoing; and consumers in class actions.

For more information, please contact Bruce Vincent at 800.559.4534 or Susan Knape at 214.523.6226.

SOURCE Baron & Budd, P.C.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
(Date:12/1/2015)... , ... December 01, 2015 , ... ... leadless pacemakers in the U.S. and is the only hospital in the region ... largest clinical data presentation of transcatheter pacing patients were revealed recently at a ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
(Date:12/1/2015)... ... 01, 2015 , ... It’s official: Tattoo taboo is a thing of the ... among Millennials (a whopping one in three aged 18 to 25 is inked). As ... with their ink. In fact, RealSelf , the world’s largest community for learning ...
(Date:12/1/2015)... ... December 01, 2015 , ... For many X-rays taken at ... accurate interpretation by the radiologist. The marking utensils are so small, however, they ... found a way to alleviate this problem. , He developed the patent-pending MARK ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition, ... Healthcare was recognized as a finalist in the category of Digital Solutions for ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... TELTOW, Germany , December 1, 2015 ... a leading global manufacturer of eye and gaze tracking ... included SMI remote eye trackers as a component of ... assess concussions, eye sight, and medical and performance issues ... is part of SMI,s mass-market-ready eye tracking platform, which ...
(Date:12/1/2015)... , Dec. 1, 2015  Lexicon ... today that top-line data from its TELECAST ... etiprate in treating carcinoid syndrome in cancer ... the clinical benefit observed in its pivotal ... as a companion to TELESTAR primarily to ...
(Date:12/1/2015)... Dec. 1, 2015  ImmunoCellular Therapeutics, Ltd. ... Andrew Gengos , President and Chief Executive ... December 3, 2015. Mr. Gengos plans to ... program in patients with newly diagnosed glioblastoma ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
Breaking Medicine Technology: